Identification of New Markers in the Hypereosinophilic Syndrome

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05334368` - Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Phase 3
Recruiting	`NCT00044304` - Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome	Phase 2
Completed	`NCT00097370` - Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome	Phase 3
Completed	`NCT00171912` - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2
Terminated	`NCT00171860` - A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome	Phase 2
Recruiting	`NCT02581514` - Eosinophilia Diagnosis	N/A
Completed	`NCT00787384` - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes	Phase 2
Recruiting	`NCT03801434` - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders	Phase 2
Completed	`NCT00255346` - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2
Completed	`NCT03306043` - A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622	Phase 3
Recruiting	`NCT04018118` - Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Completed	`NCT02836496` - Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)	Phase 3
Completed	`NCT00086658` - Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)	Phase 3
Recruiting	`NCT00276926` - Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias	Phase 2
Active, not recruiting	`NCT02101138` - Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome	Phase 2
Recruiting	`NCT00091871` - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Completed	`NCT00017862` - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome	Phase 2
Completed	`NCT00038675` - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	N/A
Terminated	`NCT00230334` - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome	Phase 2
Recruiting	`NCT04191304` - A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)	Phase 3

NCT number	NCT01713504
Study type	Interventional
Source	University Hospital, Lille
Contact
Status	Completed
Phase	N/A
Start date	June 29, 2010
Completion date	July 2015

Identification of New Markers in the Hypereosinophilic Syndrome — SHE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms